GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Total Current Liabilities

Better Therapeutics (Better Therapeutics) Total Current Liabilities : $12.94 Mil (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Better Therapeutics's total current liabilities for the quarter that ended in Sep. 2023 was $12.94

Better Therapeutics Total Current Liabilities Historical Data

The historical data trend for Better Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Better Therapeutics Total Current Liabilities Chart

Better Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Total Current Liabilities
0.49 0.61 4.73 13.49

Better Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.31 13.49 13.64 13.87 12.94

Better Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Better Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=8.962+4.532
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=13.49

Better Therapeutics's Total Current Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=6.352+6.586
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=12.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Better Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Better Therapeutics (Better Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Total Current Liabilities
Comparable Companies
CYCN CELZ NRSN EMMA FNCH TTNP LIXT ALRN CUBT JAGX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Website
https://www.bettertx.com
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.
Executives
Elder Granger director 5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman officer: Chief Medical Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe director, officer: See Remarks C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry director, 10 percent owner, officer: See Remarks 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino director C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust 10 percent owner C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen officer: See Remarks 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum director, 10 percent owner, officer: Chief Executive Officer 4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu director 311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski officer: Chief Commercial Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds officer: Chief Product Officer 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona director 1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust 10 percent owner 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104

Better Therapeutics (Better Therapeutics) Headlines

From GuruFocus

Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes

By Business Wire Business Wire • 07-26-2022

Better Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 14, 2022

By Business Wire Business Wire • 11-07-2022

Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes

By Business Wire • 10-16-2023

Thinking about buying stock in MingZhu Logistics Holdings, MMTec, Better Therapeutics, PCTEL, or Streamline Health Solutions?

By PRNewswire • 10-17-2023

Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share

By Business Wire • 07-25-2023

Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

By Business Wire • 09-28-2023

Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions

By Business Wire • 11-28-2023

Better Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, Austria

By Business Wire Business Wire • 06-16-2023

Thinking about buying stock in Oncolytics Biotech, Nikola Corp, Joby Aviation, Ideanomics, or Better Therapeutics?

By PRNewswire • 07-11-2023

Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results

By Business Wire Business Wire • 12-08-2022